Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Abstract Background It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment strategies in the real-world practice and to estimate...

Full description

Bibliographic Details
Main Authors: Radek Lakomy, Alexandr Poprach, Zbynek Bortlicek, Bohuslav Melichar, Renata Chloupkova, Rostislav Vyzula, Milada Zemanova, Katerina Kopeckova, Marek Svoboda, Ondrej Slaby, Igor Kiss, Hana Studentova, Jaroslav Juracek, Ondrej Fiala, Jindrich Kopecky, Jindrich Finek, Ladislav Dusek, Karel Hejduk, Tomas Buchler
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Cancer
Subjects:
Renal cell carcinoma
Therapy
Sunitinib
Sorafenib
Everolimus
Pazopanib
Online Access:http://link.springer.com/article/10.1186/s12885-017-3901-5

Internet

http://link.springer.com/article/10.1186/s12885-017-3901-5

Similar Items